Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Elbi

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Molecular and Cellular Biology|July 1, 2004
Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteinsRobert D Phair, Paola Scaffidi, Cem Elbi, et al.
Journal of Patient-Reported Outcomes|June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Annals of the New York Academy of Sciences|July 22, 2004
Subnuclear trafficking and gene targeting by steroid receptorsAkhilesh K Nagaich, Geetha V Rayasam, Elisabeth D Martinez, et al.
Oncogene|May 18, 2005
Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancerCeren G Korkmaz, Kemal S Korkmaz, Piotr Kurys, et al.
Scientific Reports|June 27, 2024
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesotheliomaCharles S Cleeland, Karen N Keating, Brian Cuffel, et al.
Oncogene|April 13, 2004
Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubinsMarie Knockaert, Marc Blondel, Stéphane Bach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion studyAlessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Molecular and Cellular Biology|July 1, 2004
Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteinsRobert D Phair, Paola Scaffidi, Cem Elbi, et al.
Journal of Patient-Reported Outcomes|June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Annals of the New York Academy of Sciences|July 22, 2004
Subnuclear trafficking and gene targeting by steroid receptorsAkhilesh K Nagaich, Geetha V Rayasam, Elisabeth D Martinez, et al.
Oncogene|May 18, 2005
Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancerCeren G Korkmaz, Kemal S Korkmaz, Piotr Kurys, et al.
Scientific Reports|June 27, 2024
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesotheliomaCharles S Cleeland, Karen N Keating, Brian Cuffel, et al.
Oncogene|April 13, 2004
Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubinsMarie Knockaert, Marc Blondel, Stéphane Bach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion studyAlessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Pageof 3